BIIB
BIOGEN INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 9 ▼ 1 insider sell $531.5K at $199.83
- Feb 12 ▲ 1 insider buy $585.11 at $195.04
- Mar 28 ▲ Biogen announced positive Phase 2 results from the AMETHYST study of…
- May 11 to May 15 ▲ 3 buys: Maria Elvira Salazar, Ro Khanna bought, last disclosed Jun 11
- May 27 to Jun 2 ▼ 2 sells: Ro Khanna, Maria Elvira Salazar sold, last disclosed Jul 8
- Jun 30 ▲ 4 funds open new positions (13F)
- Jul 29 HSR Early Termination: Biogen Inc.; RayThera, Inc.
- Aug 3 to Aug 4 ▼ 2 days of insider sells: $239.7K by 1 insider, avg $202.15
- Sep 11 to Sep 24 ▼ 2 sells: Ro Khanna, Maria Elvira Salazar sold $1,001 - $15,000, last disclosed Oct 9
- Oct 29 ▲ Argus Research upgrades
- Nov 9 FDA: ACR 2026: Dapirolizumab Pegol Associated with Greater Trea…
- Nov 12 Contract: LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Av…
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider bought $585.11 at an average $195.04. 2 insiders sold $771.3K. Price is 29% above their cost.
- InstitutionsMIXED
Q2 2026: 47 added (4 new), 33 trimmed or exited. Largest new: Freestone Grove Partners $18.1M, D. E. Shaw & ., $16.1M.
- AnalystsBULLISH
32 of 44 rate it Buy or better. Median target $271.00 (+8%).
- Short sellersSTEADY
Short interest −0.9% to 5.45M shares. 4.0 days to cover, ≈3.7% of shares.
- TrendUPTREND
8% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 24.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | ADD | $3.9B |
| Amundi | ADD | $327.7M |
| Boston Partners | TRIM | $272.8M |
| UBS Group AG | ADD | $222.6M |
| CITIGROUP INC | ADD | $158.7M |
| ROYAL BANK OF CANADA | ADD | $153.1M |
| CITADEL ADVISORS LLC | DOUBLED | $90.4M |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | $57.3M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
44 analystsPrice is inside the target range. Median implies +8%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 9, 2026 | Piper Sandler REITERATE | Overweight |
| Nov 2, 2026 | Guggenheim MAINTAIN | Buy |
| Nov 2, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Oct 29, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Oct 29, 2026 | Argus Research UPGRADE | Buy |
| Oct 29, 2026 | RBC Capital MAINTAIN | Outperform |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Grogan Jane Head of Research Oct 30, 2026 | EXERCISE | 695 sh |
Grogan Jane Head of Research Oct 30, 2026 | TAX W/H | $87.5K |
Godbout Sean Chief Accounting Officer Oct 2, 2026 | EXERCISE | 27 sh |
Godbout Sean Chief Accounting Officer Oct 2, 2026 | TAX W/H | $1.8K |
Godbout Sean Chief Accounting Officer Oct 1, 2026 | AWARD | 985 sh |
Parini Michael Chief Legal Officer Sep 1, 2026 | AWARD | 7,405 sh |
Minor Lloyd Director Aug 4, 2026 | SELL | $119.2K |
Minor Lloyd Director Aug 3, 2026 | SELL | $120.6K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
13 filings · 21 press releases · 6 bullish · 0 bearish · 1 mixed · 6 neutral- NEUTRAL PRESS RELEASENov 12, 2026
Eisai and Biogen launched LEQEMBI Pen, the subcutaneous autoinjector formulation of lecanemab, in…
Monitor Japan sales uptake of LEQEMBI Pen and potential reimbursement expansion; the SC formulation may broaden patient access and reduce treatment burden, but no revenue guidance was provided.
- NEUTRAL SC 13GNov 10, 2026
State Street Corporation filed a Schedule 13G disclosing beneficial ownership of 7,570,589 shares…
State Street's passive 5.1% stake is consistent with its role as a large institutional custodian and asset manager. No change in investment strategy is signaled. Monitor for any future 13D…
- NEUTRAL PRESS RELEASENov 9, 2026
Biogen and UCB presented post-hoc analyses of the Phase 3 PHOENYCS GO trial of dapirolizumab pegol…
These post-hoc analyses support the efficacy profile of DZP but are not from a pre-specified endpoint or regulatory submission. The next catalyst is the ongoing Phase 3 program; watch for regulatory…
- NEUTRAL INST-CLUSTEROct 28, 2026
Three small asset managers added Biogen positions in Q3 2026, while two others trimmed. The…
The institutional moves are small and mixed, with no insider buying to corroborate conviction. The cluster is dominated by small asset managers, not large active funds. Monitor next quarter's 13F…
All BIIB filing & press-release reports (34)
- PRESS-RELEASE reportNov 12, 2026
- SC 13G reportNov 10, 2026
- PRESS-RELEASE reportNov 9, 2026
- INST-CLUSTER reportOct 28, 2026
- 8-K reportOct 28, 2026
- PRESS-RELEASE reportOct 19, 2026
- JP Morgan upgrades BIIB to Overweight, PT $300 (+29.5%)Oct 12, 2026
- PRESS-RELEASE reportOct 2, 2026
- PRESS-RELEASE reportSep 17, 2026
- PRESS-RELEASE reportSep 3, 2026
- PRESS-RELEASE reportSep 3, 2026
- PRESS-RELEASE reportAug 6, 2026
- PRESS-RELEASE reportJul 14, 2026
- PRESS-RELEASE reportJul 13, 2026
- Truist Securities upgrades BIIB to Buy, PT $235 (+18%)Jul 13, 2026
- PRESS-RELEASE reportJun 17, 2026
- Needham upgrades BIIB to Buy, PT $255 (+30.5%)Jun 8, 2026
- PRESS-RELEASE reportJun 4, 2026
- PRESS-RELEASE reportJun 1, 2026
- PRESS-RELEASE reportMay 21, 2026
- PRESS-RELEASE reportMay 14, 2026
- 8-K reportMay 14, 2026
- PRESS-RELEASE reportMay 14, 2026
- PRESS-RELEASE reportMay 8, 2026
- DEFA14A reportApr 28, 2026
- UBS double upgrades NVDA to Buy, PT $225 (+21%)Apr 22, 2026
- 8-K reportApr 6, 2026
- Wells Fargo double upgrades to Overweight with $250 PT, +41% upsideApr 20, 2026
- PRESS-RELEASE reportApr 20, 2026
- PRESS-RELEASE reportMar 31, 2026
- COURT-RULING reportMar 30, 2026
- PRESS-RELEASE reportMar 28, 2026
- PRESS-RELEASE reportMar 19, 2026
- 8-K reportMar 11, 2026